# CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2

> **NIH NIH UM1** · FRED HUTCHINSON CANCER RESEARCH CENTER · 2021 · $978,683

## Abstract

Abstract
The proposed research, CoVPN 5002, will directly contribute to preparedness for SARS-CoV-2
vaccine and other COVID-19 prevention and treatment studies by determining the prevalence of
SARS-CoV-2 infection and seroprevalence among samples of individuals at elevated risk as well as
the general population. This research will determine the extent to which children and adults in the
study communities have SARS-CoV-2 infection or evidence of prior SARS-CoV-2 infection (based on
antibody tests, self-report, and medical records). Additionally, about participants’ household members
with COVID-like illness and deaths, combined with serologic data from participants, may also provide
information about transmission dynamics within households. Questionnaire data will inform estimates
of the percent of individuals of different age groups, including children, who may have had an
asymptomatic COVID-19 infection. The frequency of infection among children and whether children
play an important role in community transmission is poorly understood. The study will also estimate
the association of SARS-CoV-2 seroprevalence with medical co-morbidities associated with more
severe disease outcomes and identify demographic and social risk factors associated with infection.
Finally, this research will provide important information about SARS-CoV-2 transmission, COVID-19
disease, attitudes about and uptake of containment and mitigation measures, racial and ethnic health
disparities, varied access to testing and public health resources by key demographic
indicators, prospects for new prevention and treatment strategies, and inform mathematical models of
disease progression and projection of future COVID-19 risk.
The HPTN SDMC, housed at the Fred Hutchinson Cancer Research Center in Seattle, takes
advantage of the strengths of the institution, which also includes the HVTN SDMC. The HPTN SDMC
has faculty biostatisticians experienced in the design, conduct and analysis of global clinical trials and
surveillance studies, who support research through leadership in statistical design, trial conduct and
analysis, and development and implementation of innovative statistical methods as needed and
motivated by the scientific goals. The SDMC provides regulatory compliant data management
functions for all trials it implements, including electronic data capture directly from research sites or
the field, integration of laboratory specimens and assay results, and electronic participant reported
outcomes.

## Key facts

- **NIH application ID:** 10308340
- **Project number:** 3UM1AI068617-15S1
- **Recipient organization:** FRED HUTCHINSON CANCER RESEARCH CENTER
- **Principal Investigator:** Deborah J Donnell
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $978,683
- **Award type:** 3
- **Project period:** 2021-04-02 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10308340

## Citation

> US National Institutes of Health, RePORTER application 10308340, CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 (3UM1AI068617-15S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10308340. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*